Top 10 Chronic Pain Drug Companies Advancing Non-Opioid and Personalized Therapies

Chronic pain drugs were previously drawn from plants such as willow bark to soothe discomfort. This practice laid the foundation for modern advancements. With time, scientists isolated salicylic acid from these sources, leading to the introduction of aspirin which is a compound that quelled pain and fever through clear chemical action. This progress further continued with the rise of opioids and anti-inflammatories, refining control over pain's mechanisms. Currently, different companies lead the charge with innovative non-opioid drugs that target specific receptors, offering safer paths to relief.

New technologies including microfluidic devices deliver drugs precisely, and CRISPR-based edits explore altering pain genes.  Moreover, the industry is evolving rapidly due to altering patient needs and growing focus of healthcare providers on long-term pain management. Increasing awareness of pain-concerned conditions and significance of healthy lifestyle has led to surging product demand globally. Moreover, supportive regulatory standards and ongoing investments in research and product development creates opportunities for companies to expand their presence.

Fortune Business Insights reported that the industry for chronic pain drugs is noticing a substantial growth with a CAGR of 4.01% and is expected to reach a revenue share of USD 54.60 billion in 2026 to USD 74.80 billion by 2034.

List of Top 10 Chronic Pain Drug Companies Reported by Fortune Business Insights

1. Viatris Inc.

Viatris Inc., headquartered in the U.S., is a diversified global pharmaceutical company with a broad presence across established medicines, generics, and selected specialty therapies. Within chronic pain drugs, its most significant program that centers on fast-acting meloxicam, a non-opioid medication designed for moderate-to-severe pain control. Viatris reported positive Phase III results for this formulation and targeted regulatory filing later that year. The company is targeting to build value through practical therapies, large-scale access, and a pipeline aimed at unmet pain needs.

2. Eli Lilly and Company

Eli Lilly and Company, one of the top 10 chronic pain drug companies, remains a major biopharmaceutical developer with strong capabilities in neuroscience, immunology, and cardiometabolic care. Its chronic pain involvement is associated with research programs that support pain modulation and patient management. Headquartered in the U.S., Lilly expanded development activity across core therapeutic areas and reinforced its global research base. The company’s scale, clinical expertise, and innovation capacity keep it relevant to future chronic pain treatment pathways.

3. AbbVie Inc.

AbbVie Inc., headquartered in the U.S., is a large research-based pharmaceutical company with a significant role in pain management through anti-inflammatory and neurological therapies. Its chronic pain drugs’ presence is supported by products and development programs that address long-term discomfort and related conditions. AbbVie is modernizing its specialty medicine portfolio after the Allergan integration, thus increasing therapeutic reach. The company operates chronic pain care through deep clinical expertise, strong commercial execution, and a focus on ongoing patient needs.

4. Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is one of the most established generics and specialty medicine companies in chronic pain drugs. Its portfolio includes pain-focused therapies and delivery formats aimed at long-term symptom management and broad patient access. Headquartered in Israel, Teva is restructuring while strengthening key branded and generic product lines. The company’s role in this industry reflects its growing focus on affordability, global distribution, and practical treatment options for chronic and neuropathic pain. In August 2025, the company stated that it received an expanded indication from the U.S. FD for AJOVY for avoiding treatment of episodic migraine in pediatric patients.

5. Amgen Inc.

Amgen Inc., headquartered in the U.S., offers chronic pain drugs through biologics and research tied to inflammatory pathways and pain-related conditions. Its larger portfolio includes therapies that can support patients living with long-term pain related to immune or neurological disease. Amgen supports its pipeline and increasing clinical programs across major therapeutic areas. The company’s position in chronic pain highlights a science-driven approach, where biologic innovation and disease modification can guide pain outcomes over time.

6. Lundbeck A/S

Lundbeck A/S focuses strongly on central nervous system therapies, which gives it a clear place in chronic pain-related treatment areas. Headquartered in Denmark, its products and research address neurological conditions that often overlap with persistent pain and patient quality-of-life issues. Lundbeck is investing in neuroscience assets and global commercialization. The company’s strength lies in its focused therapeutic effort, long clinical experience, and ability to support patients with complex, chronic conditions that include pain.

7. Grünenthal GmbH

Grünenthal GmbH, headquartered in Germany, is an expert in pain management and one of the most focused companies in the segment. Its portfolio includes therapies for acute, neuropathic, and long-term pain, reinforced by strong clinical expertise and patient-centered development. Grünenthal is expanding internationally and strengthening branded pain assets.

8. Collegium Pharmaceutical, Inc.

Headquartered in the U.S., Collegium Pharmaceutical, Inc. is a focused specialty pharmaceutical company centered on pain management and related treatment needs. Its chronic pain offering includes Xtampza ER, a tamper-resistant extended-release oxycodone designed for persistent pain requiring around-the-clock opioid therapy.

9. Haleon plc

Haleon plc, headquartered in the U.K., operates in consumer health and contributes to chronic pain relief through over-the-counter analgesics and self-care solutions. Its product range includes widely recognized pain remedies that help monitor recurring discomfort without prescription use. Haleon is expanding its consumer health portfolio and global brand presence by portfolio simplification after separation from GSK. The company’s role in chronic pain rests on accessible, normal symptom relief and trusted household brands.

10. Kenvue Inc.

Kenvue Inc., headquartered in the U.S., serves the chronic pain space through over-the-counter pain relief products used for everyday and frequent discomfort. Its portfolio includes well-known analgesic brands that support self-care for headaches, muscle pain, and other basic pain conditions. Since its 2023 separation from Johnson & Johnson, Kenvue is refining its consumer health focus and brand investment.

Increasing Focus on AI and Personalized Treatment Reshapes the Future of Chronic Pain Drugs Industry

The future of chronic pain drugs points toward a coordination between human needs and scientific tools. Top companies are looking for different adaptive implants that sense and respond to pain shifts instantly. In future, personalized treatments will be recognized from blood tests and AI scans to craft drugs suited to one's biology, thus cutting trial-and-error concepts. Through new technologies, the top 10 chronic pain drug companies are expected to craft the future for drugs. Moreover, a stronger distribution network majorly across emerging economies will also boost the product accessibility. Collaborations among the industry participants, research organizations, and healthcare providers is likely to aid broad industry reach and product availability.